Mucosal treatments for herpes simplex virus: Insights on targeted immunoprophylaxis and therapy

Future Microbiology

Volumn 5, Issue 1, 2010, Pages 15-22

  McGowin, Chris L ^a   Pyles, Richard B ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Genital herpes immunotherapy; Herpes simplex; HSV 1; HSV 2; Keratitis mucosa; Therapy; TLR

Indexed keywords

ACICLOVIR; CD14 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; FAMCICLOVIR; GAMMA GLUTAMYLTRYPTOPHAN; GLYCOPROTEIN D; IMIQUIMOD; MYELOID DIFFERENTIATION FACTOR 88; POLYINOSINIC POLYCYTIDYLIC ACID; RESIQUIMOD; SCV 07; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9; TRYPTOPHAN; UNCLASSIFIED DRUG; VALACICLOVIR;

BLINDNESS; CLINICAL TRIAL; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTYPE; VIRUS REACTIVATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

CHEMOPREVENTION; HERPES SIMPLEX; HERPESVIRUS VACCINES; HUMANS; IMMUNOLOGIC FACTORS; MUCOUS MEMBRANE;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 75849117856     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.111     Document Type: Review

References (68)

1. Lafferty WE: The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing. Herpes 9(2), 51-55 (2002).
2. Liesegang TJ: Herpes simplex virus epidemiology and ocular importance. Cornea 20(1), 1-13 (2001).
3. Looker KJ, Garnett GP: A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex. Transm. Infect. 81(2), 103-107 (2005).
4. Looker KJ, Garnett GP, Schmid GP: An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ. 86(10), 805-812, A (2008).
5. Xu F, Sternberg MR, Kottiri BJ et al.: Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296(8), 964-973 (2006).
6. Smith JS, Robinson NJ: Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186(Suppl. 1), S3-S28 (2002).
7. Gupta R, Warren T, Wald A: Genital herpes. Lancet 370(9605), 2127-2137 (2007).
8. Labetoulle M, Kucera P, Ugolini G et al.: Neuronal propagation of HSV1 from the oral mucosa to the eye. Invest. Ophthalmol. Vis. Sci. 41(9), 2600-2606 (2000).
9. Summers BC, Margolis TP, Leib DA: Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread. J. Virol. 75(11), 5069-5075 (2001).
10. Rosenthal SL, Zimet GD, Leichliter JS et al.: The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex. Transm. Infect. 82(2), 154-157; discussion 157-158 (2006).
11. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL: The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect. Sex. Reprod. Health 36(1), 11-19 (2004).
12. Szucs TD, Berger K, Fisman DN, Harbarth S: The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches. BMC Infect. Dis. 1, 5 (2001).
13. Whitley RJ, Roizman B: Herpes simplex virus infections. Lancet 357(9267), 1513-1518 (2001).
14. Corey L, Wald A, Celum CL, Quinn TC: The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. 35(5), 435-445 (2004).
15. Stanberry LR: Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11(Suppl. 3), 161A-169A (2004).
16. Stanberry LR, Spruance SL, Cunningham AL et al.: Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347(21), 1652-1661 (2002).
17. Magaret AS, Johnston C, Wald A: Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex. Transm. Infect. 85(4), 270-275 (2009).
18. Wald A, Selke S, Warren T et al.: Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex. Transm. Dis. 33(9), 529-533 (2006).
19. Stanberry L, Cunningham A, Mertz G et al.: New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res. 42(1), 1-14 (1999).
20. Corey L, Wald A, Patel R et al.: Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 350(1), 11-20 (2004).
21. Crespi CM, Cumberland WG, Wald A, Corey L, Blower S: Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex. Transm. Infect. 83(5), 359-364 (2007).
22. Wald A, Carrell D, Remington M et al.: Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin. Infect. Dis. 34(7), 944-948 (2002).
23. Lakeman AD, Nahmias AJ, Whitley RJ: Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion. Sex. Transm. Dis. 13(2), 61-66 (1986).
24. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
25. Fazeli A, Bruce C, Anumba DO: Characterization of Toll-like receptors in the female reproductive tract in humans. Hum. Reprod. 20(5), 1372-1378 (2005).
26. Fichorova RN, Cronin AO, Lien E, Anderson DJ, Ingalls RR: Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of Toll-like receptor 4-mediated signaling. J. Immunol. 168(5), 2424-2432 (2002).
27. Herbst-Kralovetz MM, Quayle AJ, Ficarra M et al.: Quantification and comparison of Toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia. Am. J. Reprod. Immunol. 59(3), 212-224 (2008).
28. Pioli PA, Amiel E, Schaefer TM et al.: Differential expression of Toll-like receptors 2 and 4 in tissues of the human female reproductive tract. Infect. Immun. 72(10), 5799-5806 (2004).
29. Pivarcsi A, Nagy I, Koreck A et al.: Microbial compounds induce the expression of pro-inflammatory cytokines, chemokines and human b-defensin-2 in vaginal epithelial cells. Microbes Infect. 7(9-10), 1117-1127 (2005).
30. Schaefer TM, Desouza K, Fahey JV, Beagley KW, Wira CR: Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 112(3), 428-436 (2004).
31. Diamond G, Beckloff N, Ryan LK: Host defense peptides in the oral cavity and the lung: similarities and differences. J. Dent. Res. 87(10), 915-927 (2008).
32. Kumar A, Yu FS: Toll-like receptors and corneal innate immunity. Curr. Mol. Med. 6(3), 327-337 (2006).
33. Pearlman E, Johnson A, Adhikary G et al.: Toll-like receptors at the ocular surface. Ocul. Surf. 6(3), 108-116 (2008).
34. Morrison LA: The Toll of herpes simplex virus infection. Trends Microbiol. 12(8), 353-356 (2004).
35. Mogensen TH: Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22(2), 240-273 (2009).
36. Gill N, Davies EJ, Ashkar AA: The role of Toll-like receptor ligands/agonists in protection against genital HSV-2 infection. Am. J. Reprod. Immunol. 59(1), 35-43 (2008).
37. Herbst-Kralovetz M, Pyles R: Toll-like receptors, innate immunity and HSV pathogenesis. Herpes 13(2), 37-41 (2006).
38. Miller RL, Meng TC, Tomai MA: The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 21(2), 69-87 (2008).
39. Miller RL, Tomai MA, Harrison CJ, Bernstein DI: Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int. Immunopharmacol. 2(4), 443-451 (2002).
40. Hemmi H, Kaisho T, Takeuchi O et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196-200 (2002).
41. Bernstein DI, Harrison CJ, Tepe ER, Shahwan A, Miller RL: Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs. Vaccine 13(1), 72-76 (1995).
42. Bernstein DI, Spruance SL, Arora SS, Schroeder JL, Meng TC: Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin. Infect. Dis. 41(6), 808-814 (2005).
43. Mark KE, Corey L, Meng TC et al.: Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis. 195(9), 1324-1331 (2007).
44. Pyles RB, Higgins D, Chalk C et al.: Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J. Virol. 76(22), 11387-11396 (2002).
45. Harandi AM: The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges. J. Clin. Virol. 30(3), 207-210 (2004).
46. Herbst MM, Pyles RB: Immunostimulatory CpG treatment for genital HSV-2 infections. J. Antimicrob. Chemother. 52(6), 887-889 (2003).
47. Sajic D, Ashkar AA, Patrick AJ et al.: Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J. Med. Virol. 71(4), 561-568 (2003).
48. Herbst-Kralovetz MM, Pyles RB: Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J. Virol. 80(20), 9988-9997 (2006).
49. Ashkar AA, Yao XD, Gill N et al.: Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J. Infect. Dis. 190(10), 1841-1849 (2004).
50. Kurt-Jones EA, Chan M, Zhou S et al.: Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc. Natl Acad. Sci. USA 101(5), 1315-1320 (2004).
51. Gill N, Deacon PM, Lichty B, Mossman KL, Ashkar AA: Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with b interferon production. J. Virol. 80(20), 9943-9950 (2006).
52. Rose WA 2nd, McGowin CL, Pyles RB: FSL 1, a bacterial-derived Toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol. J. 6, 195 (2009).
53. Rose WA 2nd, Tuthill C, Pyles RB: An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int. J. Antimicrob. Agents 32(3), 262-266 (2008).
54. Nazli A, Yao XD, Smieja M et al.: Differential induction of innate anti-viral responses by TLR ligands against herpes simplex virus, type 2, infection in primary genital epithelium of women. Antiviral Res. 81(2), 103-112 (2009).
55. Meyer T, Stockfleth E: Clinical investigations of Toll-like receptor agonists. Expert Opin. Invest. Drugs 17(7), 1051-1065 (2008).
56. Pepose JS, Keadle TL, Morrison LA: Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am. J. Ophthalmol. 141(3), 547-557 (2006).
57. Kumar M, Hill JM, Clement C et al.: A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva. Invest. Ophthalmol. Vis. Sci. 50(12), 5601-5608 (2009).
58. Toma HS, Murina AT, Areaux RG Jr et al.: Ocular HSV-1 latency, reactivation and recurrent disease. Semin. Ophthalmol. 23(4), 249-273 (2008).
59. Nesburn AB, Bettahi I, Zhang X et al.: Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 4(4), 178-187 (2006).
60. Jin X, Qin Q, Chen W, Qu J: Expression of Toll-like receptors in the healthy and herpes simplex virus-infected cornea. Cornea 26(7), 847-852 (2007).
61. Van de Perre P, Segondy M, Foulongne V et al.: Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect. Dis. 8(8), 490-497 (2008).
62. Coleman CM, Wu L: HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6, 51 (2009).
63. de Jong MA, de Witte L, Oudhoff MJ et al.: TNF a and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J. Clin. Invest. 118(10), 3440-3452 (2008).
64. Bafica A, Scanga CA, Schito ML, Hieny S, Sher A: Cutting edge: in vivo induction of integrated HIV-1 expression by mycobacteria is critically dependent on Toll-like receptor 2. J. Immunol. 171(3), 1123-1127 (2003).
65. Equils O, Schito ML, Karahashi H et al.: Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J. Immunol. 170(10), 5159-5164 (2003).
66. Fichorova RN: Guiding the vaginal microbicide trials with biomarkers of inflammation. J. Acquir. Immune Defic. Syndr. 37(Suppl. 3), S184-S193 (2004).
67. Rosenthal KL, Gallichan WS: Challenges for vaccination against sexually-transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract. Semin. Immunol. 9(5), 303-314 (1997).
68. Dasgupta G, Chentoufi AA, Nesburn AB, Wechsler SL, BenMohamed L: New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev. Vaccines 8(8), 1023-1035 (2009).